Parker Institute for Cancer Immunotherapy shared a post on X:
“Few cancers rob young lives of time like Ewing sarcoma. New Scientific Reports research led by PICI Investigator Beatriz Carreno, PhD (Penn Medicine), with contributions from Gerald P. Linette, MD, PhD, and Carl June, MD, reveals LOXHD1 as a tumor-specific target for immunotherapy. Supported by Parker Institute for Cancer Immunotherapy.”
Title: LOXHD1 is an oncofusion-regulated antigen of Ewing sarcoma
Authors: Tatiana Blanchard, Pouya Faridi, Chong Xu, Adham S. Bear, Reyaz ur Rasool, Grace Huang, Terry C. C. Lim, Rochelle Ayala, Khatuna Gabunia, Mei Ji, Avery D. Posey Jr, John Scholler, Irfan A. Asangani, Anthony W. Purcell, Gerald P. Linette, Carl H. June and Beatriz M. Carreno.
You can read the Full Article on Scientific Reports.
Read about Ewing Sarcoma on OncoDaily.
More posts featuring Parker Institute for Cancer Immunotherapy.